Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : NIAID
Deal Size : Undisclosed
Deal Type : Agreement
Drug Farm and NIH Partner to Develop Treatment for ROSAH Syndrome
Details : Under the terms of the agreement, Drug Farm will partner with NIAID to develop DF-003, a precision-targeted drug for the treatment of ROSAH syndrome.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 19, 2024
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : NIAID
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Drug Farm Gets IND Clearance for Phase 1b of DF-003 in ROSAH Syndrome Patients
Details : DF-003 is a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor, which is curently being evaluated for the treatment of ROSAH syndrome.
Product Name : DF-003
Product Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2024
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Drug Farm Receives Rare Pediatric Disease Designation for Df-003 To Treat Rosah Syndrome
Details : DF-003, a potent small molecule inhibitor of ALPK1, is in Phase 1 development for the treatment of ROSAH Syndrome, targeting immunity and inflammation.
Product Name : DF-003
Product Type : Small molecule
Upfront Cash : Not Applicable
January 13, 2024
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Drug Farm Doses First Patient in Phase 1 Trial for ALPK1 Inhibitor, DF-003
Details : DF-003, discovered through Drug Farms’ IDInVivo and MedChem5 platform technologies, is an investigational small molecule drug that inhibits alpha-kinase 1 (ALPK1), a key target regulating inflammation pathways that underly disease pathology in cardio-r...
Product Name : DF-003
Product Type : Small molecule
Upfront Cash : Not Applicable
September 19, 2023
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DF-003 is a highly potent first-in-class, oral investigational inhibitor of ALPK1 and the ALPK1 T237M driver mutation that causes disease in ROSAH syndrome patients.
Product Name : DF-003
Product Type : Small molecule
Upfront Cash : Not Applicable
June 29, 2023
Lead Product(s) : 8-Bromo-pet-cyclic gmps
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable